Logo image of ACIU

AC IMMUNE SA (ACIU) Stock Fundamental Analysis

NASDAQ:ACIU - Nasdaq - CH0329023102 - Common Stock - Currency: USD

2.14  +0.06 (+2.88%)

After market: 2.14 0 (0%)

Fundamental Rating

3

Taking everything into account, ACIU scores 3 out of 10 in our fundamental rating. ACIU was compared to 551 industry peers in the Biotechnology industry. The financial health of ACIU is average, but there are quite some concerns on its profitability. ACIU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACIU had negative earnings in the past year.
ACIU had a positive operating cash flow in the past year.
ACIU had negative earnings in each of the past 5 years.
ACIU had negative operating cash flow in 4 of the past 5 years.
ACIU Yearly Net Income VS EBIT VS OCF VS FCFACIU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -24.67%, ACIU is in the better half of the industry, outperforming 73.32% of the companies in the same industry.
With a decent Return On Equity value of -54.94%, ACIU is doing good in the industry, outperforming 62.43% of the companies in the same industry.
Industry RankSector Rank
ROA -24.67%
ROE -54.94%
ROIC N/A
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ACIU Yearly ROA, ROE, ROICACIU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACIU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACIU Yearly Profit, Operating, Gross MarginsACIU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

4

2. Health

2.1 Basic Checks

ACIU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACIU has been increased compared to 1 year ago.
ACIU has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ACIU is higher compared to a year ago.
ACIU Yearly Shares OutstandingACIU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACIU Yearly Total Debt VS Total AssetsACIU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -2.04, we must say that ACIU is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ACIU (-2.04) is comparable to the rest of the industry.
ACIU has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 0.11, ACIU belongs to the best of the industry, outperforming 96.37% of the companies in the same industry.
ACIU has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
ACIU has a worse Debt to Equity ratio (0.04) than 61.16% of its industry peers.
Even though the debt/equity ratio score it not favorable for ACIU, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.11
Altman-Z -2.04
ROIC/WACCN/A
WACC4.99%
ACIU Yearly LT Debt VS Equity VS FCFACIU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ACIU has a Current Ratio of 1.53. This is a normal value and indicates that ACIU is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.53, ACIU is doing worse than 80.94% of the companies in the same industry.
A Quick Ratio of 1.53 indicates that ACIU should not have too much problems paying its short term obligations.
ACIU has a worse Quick ratio (1.53) than 80.58% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.53
ACIU Yearly Current Assets VS Current LiabilitesACIU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.11% over the past year.
The Revenue has grown by 91.20% in the past year. This is a very strong growth!
Measured over the past years, ACIU shows a very negative growth in Revenue. The Revenue has been decreasing by -24.39% on average per year.
EPS 1Y (TTM)13.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
Revenue 1Y (TTM)91.2%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%N/A

3.2 Future

ACIU is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 37.94% yearly.
The Revenue is expected to grow by 55.53% on average over the next years. This is a very strong growth
EPS Next Y-50.52%
EPS Next 2Y-10.47%
EPS Next 3Y29.97%
EPS Next 5Y37.94%
Revenue Next Year-86.77%
Revenue Next 2Y-8.46%
Revenue Next 3Y55.88%
Revenue Next 5Y55.53%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ACIU Yearly Revenue VS EstimatesACIU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M 200M 250M
ACIU Yearly EPS VS EstimatesACIU Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ACIU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACIU. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACIU Price Earnings VS Forward Price EarningsACIU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, ACIU is valued cheaply inside the industry as 99.27% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.83
EV/EBITDA N/A
ACIU Per share dataACIU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

ACIU's earnings are expected to grow with 29.97% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.47%
EPS Next 3Y29.97%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACIU!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AC IMMUNE SA

NASDAQ:ACIU (8/8/2025, 8:17:56 PM)

After market: 2.14 0 (0%)

2.14

+0.06 (+2.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06
Earnings (Next)11-03 2025-11-03
Inst Owners25.38%
Inst Owner Change-2.69%
Ins Owners3.4%
Ins Owner ChangeN/A
Market Cap214.88M
Analysts88
Price Target9.52 (344.86%)
Short Float %2.25%
Short Ratio10.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.71%
Min EPS beat(2)9.14%
Max EPS beat(2)16.28%
EPS beat(4)3
Avg EPS beat(4)-8.33%
Min EPS beat(4)-183.77%
Max EPS beat(4)125.04%
EPS beat(8)5
Avg EPS beat(8)-99.25%
EPS beat(12)9
Avg EPS beat(12)-61.26%
EPS beat(16)10
Avg EPS beat(16)-68.13%
Revenue beat(2)2
Avg Revenue beat(2)125.27%
Min Revenue beat(2)50.21%
Max Revenue beat(2)200.32%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.2%
EPS NY rev (1m)0%
EPS NY rev (3m)4.42%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.13
P/FCF 3.83
P/OCF 3.77
P/B 1.83
P/tB 3.91
EV/EBITDA N/A
EPS(TTM)-0.66
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)0.56
FCFY26.1%
OCF(TTM)0.57
OCFY26.5%
SpS0.35
BVpS1.17
TBVpS0.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.67%
ROE -54.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 160.12%
ROA(3y)-29.93%
ROA(5y)-28.73%
ROE(3y)-40.33%
ROE(5y)-36.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 0.11
Debt/EBITDA N/A
Cap/Depr 31.06%
Cap/Sales 2.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.53
Altman-Z -2.04
F-Score5
WACC4.99%
ROIC/WACCN/A
Cap/Depr(3y)38.45%
Cap/Depr(5y)62.34%
Cap/Sales(3y)13.11%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.56%
EPS Next Y-50.52%
EPS Next 2Y-10.47%
EPS Next 3Y29.97%
EPS Next 5Y37.94%
Revenue 1Y (TTM)91.2%
Revenue growth 3YN/A
Revenue growth 5Y-24.39%
Sales Q2Q%N/A
Revenue Next Year-86.77%
Revenue Next 2Y-8.46%
Revenue Next 3Y55.88%
Revenue Next 5Y55.53%
EBIT growth 1Y7.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.67%
EBIT Next 3Y-16.92%
EBIT Next 5Y-10.91%
FCF growth 1Y166.51%
FCF growth 3YN/A
FCF growth 5Y4.12%
OCF growth 1Y168.43%
OCF growth 3YN/A
OCF growth 5Y3.58%